Adaptimmune LLC
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company`s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. We have generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body`s own immune system to find and destroy diseased cells.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)
- Year Founded:
- 1993
About us
Leading the TCR T-cell therapy spaceTransforming cancer immunotherapy with affinity enhanced T-cell receptors
Our SPEAR T-cell therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. Adaptimmune partners with industry leaders in all areas of its business.
Perspectives
Read perspectives from our colleagues and external experts on our work and how we are improving cancer patients’ lives.